What's new? Log in Free sign up

Annexon (ANNX)

Company Profile

Company profile

Ticker

ANNX

Exchange

Website

www.annexonbio.com

CEO

Mr. Douglas Love Esq., J.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Annexon Biosciences Australia Pty Ltd ...

IRS number

275414423

ANNX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Registration of securities for employees

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

Registration of securities for employees

Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS

Quarterly report

14 Nov 24

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients

Latest ownership filings

View all

DEAN RICHARD ARTIS

Jamie Dananberg

Michael Overdorf

Jamie Dananberg

DEAN RICHARD ARTIS

Michael Overdorf

Financial summary

Financial statements Chart ANNX financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	50.53 mm	50.53 mm	50.53 mm	50.53 mm	50.53 mm	50.53 mm
Cash burn (monthly)	10.01 mm	14.63 mm	17.49 mm	12.84 mm	12.01 mm	9.83 mm
Cash used (since last report)	23.00 mm	33.61 mm	40.17 mm	29.49 mm	27.57 mm	22.58 mm
Cash remaining	27.53 mm	16.92 mm	10.36 mm	21.04 mm	22.96 mm	27.95 mm
Runway (months of cash)	2.7	1.2	0.6	1.6	1.9	2.8

Beta Read what these cash burn values mean

Financial data from Annexon earnings reports.

Institutional ownership, Q4 2024

ANNX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	162	152	+6.6%
Opened positions	29	21	+38.1%
Closed positions	19	22	-13.6%
Increased positions	60	59	+1.7%
Reduced positions	39	39	–

13F shares	Current	Prev Q	Change
Total value	565.66 bn	637.81 bn	-11.3%
Total shares	144.26 mm	143.06 mm	+0.8%
Total puts	173.50 k	158.70 k	+9.3%
Total calls	145.60 k	178.20 k	-18.3%
Total put/call ratio	1.2	0.9	+33.8%

Largest owners	Shares	Value	Change
FMR	14.22 mm	$72.97 bn	+66.1%
Biotechnology Value Fund L P	9.03 mm	$68.07 mm	0.0%
BlackRock	8.49 mm	$43.53 bn	+11.0%
Satter Management	7.41 mm	$37.99 bn	0.0%
BVF	7.00 mm	$35.91 bn	0.0%
Redmile	6.30 mm	$32.32 bn	-2.0%
Point72 Asset Management	5.63 mm	$28.87 bn	+5.6%
Vanguard	5.55 mm	$28.46 bn	+11.6%
Bain Capital Life Sciences Fund	5.25 mm	$21.21 mm	-12.1%
Bain Capital Life Sciences Investors	5.25 mm	$26.93 bn	-37.9%

Largest transactions	Shares	Bought/sold	Change
FMR	14.22 mm	+5.66 mm	+66.1%
Bain Capital Life Sciences Investors	5.25 mm	-3.20 mm	-37.9%
Adage Capital Partners GP, L.L.C.	0.00	-2.84 mm	EXIT
GMT Capital	0.00	-1.91 mm	EXIT
Sphera Funds Management	1.24 mm	+1.24 mm	NEW
Eventide Asset Managment	1.02 mm	+1.02 mm	NEW
Sio Capital Management	2.37 mm	+933.85 k	+65.2%
BlackRock	8.49 mm	+838.47 k	+11.0%
Acadian Asset Management	155.65 k	-789.35 k	-83.5%
AMP Ameriprise Financial	926.64 k	+767.87 k	+483.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ANNX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Feb 25	Michael Overdorf	Stock Option Common Stock	Grant	Acquire A	No	No	2.5	272,575	681.44 k	272,575
27 Feb 25	Ted Yednock	Stock Option Common Stock	Grant	Acquire A	No	No	2.5	272,575	681.44 k	272,575
27 Feb 25	Douglas Love	Stock Option Common Stock	Grant	Acquire A	No	No	2.5	1,300,000	3.25 mm	1,300,000
27 Feb 25	Lew Jennifer	Stock Option Common Stock	Grant	Acquire A	No	No	2.5	272,575	681.44 k	272,575
27 Feb 25	Dananberg Jamie	Stock Option Common Stock	Grant	Acquire A	No	No	2.5	228,225	570.56 k	228,225
27 Feb 24	Michael Overdorf	Common Stock	Grant	Acquire A	No	No	0	44,963	0.00	131,542
27 Feb 24	Ted Yednock	Common Stock	Grant	Acquire A	No	No	0	44,963	0.00	106,200
27 Feb 24	Lew Jennifer	Common Stock	Grant	Acquire A	No	No	0	44,963	0.00	122,733
27 Feb 24	Dananberg Jamie	Common Stock	Grant	Acquire A	No	No	0	44,963	0.00	78,442

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Needham Reiterates Buy on Annexon, Maintains $16 Price Target

Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.

Annexon Announces 2025 Outlook, ANX005 Targets Guillain-Barré Syndrome BLA In H1 2025, ANX007 Completes Phase 3 Enrollment For Geographic Atrophy In H2 2025, ANX1502 Seeks Clinical Data In Q1 2025; Cash Runway Extends To H2 2026

ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA SubmissionANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3

HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.

Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome

Press releases

From Benzinga Pro

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.